Merck (MRK) reported Q1 FY 2018 earnings of $1.05 per share (versus $0.88 in Q1 FY 2017), beating analysts' consensus estimate of $1.00.

The company's quarterly revenues amounted to $10.037 bln (+6.4% y/y), generally in-line with analysts' consensus estimate of $10.088 bln.

The company also raised guidance for FY 2018, projecting EPS of $4.16-4.28 (compared to its prior forecast of $4.08-4.23 and analysts' consensus estimate of $4.19) and revenue of $41.8-43.0 bln (compared to its prior forecast of $41.2-42.7 bln and analysts' consensus estimate of $41.86 bln).

MRK rose to $58.90 (+0.05%) in pre-market trading.